Development of novel aptamers for low-density lipoprotein particle quantification

PLoS One. 2018 Oct 11;13(10):e0205460. doi: 10.1371/journal.pone.0205460. eCollection 2018.

Abstract

Cardiovascular disease (CVD) remains the leading cause of death worldwide. Low-density lipoprotein cholesterol (LDL-C) is commonly used for CVD risk assessment; however, recent research has shown LDL particle (LDL-P) number to be a more sensitive indicator of CVD risk than both LDL-C and non-high-density lipoprotein cholesterol (HDL-C). Described herein are five single stranded DNA aptamers with dissociation constants in the low picomolar range specific to LDL-P and its subfractions. Furthermore, a set of antisense sequences have been developed and characterized that are capable of binding to the best aptamers and undergoing displacement by LDL-P for use in a simple, affordable diagnostic assay.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aptamers, Nucleotide / genetics
  • Aptamers, Nucleotide / pharmacology*
  • Cardiovascular Diseases / blood
  • Cardiovascular Diseases / diagnosis*
  • Humans
  • Lipoproteins, LDL / analysis*
  • Lipoproteins, LDL / blood
  • Risk Factors

Substances

  • Aptamers, Nucleotide
  • Lipoproteins, LDL

Grants and funding

This study was funded by InnaMed, Inc. (www.InnaMed.com) and NeoVentures Biotechnology Inc. Members of the funding organization were involved in the design, analysis, decision to publish and preparation of the manuscript.